Patents by Inventor Philippe Guedat

Philippe Guedat has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11084783
    Abstract: The present invention relates to a compound of formula (I), or a tautomer and/or a pharmaceutically acceptable salt thereof, and its uses to treat a disorder associated with protein misfolding stress and in particular with an accumulation of misfolded proteins.
    Type: Grant
    Filed: December 2, 2019
    Date of Patent: August 10, 2021
    Assignee: INFLECTIS BIOSCIENCE
    Inventor: Philippe Guedat
  • Patent number: 10954198
    Abstract: The present invention relates to a compound of formula (I), or a tautomer and/or a pharmaceutically acceptable salt thereof, wherein: R1 is alkyl, Cl, F or Br; R2 is H or F; R3 is selected from H and alkyl; R4 is selected from H and C(O)R6; R5 is H; or R4 and R5 are linked to form a heterocyclic group which is optionally substituted with one or more R10 groups; R6 is selected from R7, OR7 and NR8R9; R7, R8 and R9 are each independently selected from alkyl, cycloalkyl, aralkyl, cycloalkenyl, heterocyclyl and aryl, each of which is optionally substituted with one or more R10 groups; each R10 is independently selected from halogen, OH, CN, NO2, COO-alkyl, aralkyl, SO2-alkyl, SO2-aryl, COOH, CO-alkyl, CO-aryl, NH2, NH-alkyl, N(alkyl)2, CF3, alkyl and alkoxy; X and Z are each independently CR11, and Y is selected from CR11 and N; and R11 is H or F; for use in treating a disorder associated with protein misfolding stress and in particular associated with accumulation of misfolded proteins.
    Type: Grant
    Filed: November 25, 2019
    Date of Patent: March 23, 2021
    Assignees: United Kingdom Research and Innovation, Inflectis Bioscience
    Inventors: Philippe Guedat, Anne Bertolotti
  • Publication number: 20200289436
    Abstract: The present invention relates to novel methods of using a compound of formula (I), or a tautomer and/or a pharmaceutically acceptable salt thereof, in treating a disorder associated with the PPP1R15A pathway and associated with protein misfolding stress and in particular with accumulation of misfolded proteins selected in the group of tauopathies, synucleinopathies, polyglutamine and polyalanine diseases, leukodystrophies, cystic fibrosis, multiple sclerosis, lysosomal storage disorders, amyloidosis diseases, inflammation, metabolic disorders, cardio-vascular disorders, osteoporosis, nervous system trauma, ischemia.
    Type: Application
    Filed: June 3, 2020
    Publication date: September 17, 2020
    Inventor: Philippe GUEDAT
  • Patent number: 10709677
    Abstract: The present invention relates to novel uses of a compound of formula (I), or a tautomer and/or a pharmaceutically acceptable salt thereof, in treating a disorder associated with the PPP1R15A pathway and associated with protein misfolding stress and in particular with accumulation of misfolded proteins selected in the group of tauopathies, synucleinopathies, polyglutamine and polyalanine diseases, leukodystrophies, cystic fibrosis, multiple sclerosis, lysosomal storage disorders, amyloidosis diseases, inflammation, metabolic disorders, cardio-vascular disorders, osteoporosis, nervous system trauma, ischemia.
    Type: Grant
    Filed: July 2, 2015
    Date of Patent: July 14, 2020
    Assignee: INFLECTIS BIOSCIENCE
    Inventor: Philippe Guedat
  • Patent number: 10675257
    Abstract: The present invention relates to a composition for use in treating a glioma or ameliorating the effects of a glioma, particularly glioblastoma, wherein said composition comprises a first active agent selected from the group consisting of a compound of formula (I), or a pharmaceutically acceptable salt thereof, (I) and a second active agent, which is temozolomide, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: July 26, 2016
    Date of Patent: June 9, 2020
    Assignee: INFLECTIS BIOSCIENCE
    Inventors: Philippe Guedat, Pierre Miniou
  • Publication number: 20200102269
    Abstract: The present invention relates to a compound of formula (I), or a tautomer and/or a pharmaceutically acceptable salt thereof, and its uses to treat a disorder associated with protein misfolding stress and in particular with an accumulation of misfolded proteins.
    Type: Application
    Filed: December 2, 2019
    Publication date: April 2, 2020
    Inventor: Philippe GUEDAT
  • Publication number: 20200095210
    Abstract: The present invention relates to a compound of formula (I), or a tautomer and/or a pharmaceutically acceptable salt thereof, wherein: R1 is alkyl, Cl, F or Br; R2 is H or F; R3 is selected from H and alkyl; R4 is selected from H and C(O)R6; R5 is H; or R4 and R5 are linked to form a heterocyclic group which is optionally substituted with one or more R10 groups; R6 is selected from R7, OR7 and NR8R9; R7, R8 and R9 are each independently selected from alkyl, cycloalkyl, aralkyl, cycloalkenyl, heterocyclyl and aryl, each of which is optionally substituted with one or more R10 groups; each R10 is independently selected from halogen, OH, CN, NO2, COO-alkyl, aralkyl, SO2-alkyl, SO2-aryl, COOH, CO-alkyl, CO-aryl, NH2, NH-alkyl, N(alkyl)2, CF3, alkyl and alkoxy; X and Z are each independently CR11, and Y is selected from CR11 and N; and R11 is H or F; for use in treating a disorder associated with protein misfolding stress and in particular associated with accumulation of misfolded proteins.
    Type: Application
    Filed: November 25, 2019
    Publication date: March 26, 2020
    Inventors: Philippe Guedat, Anne Bertolotti
  • Patent number: 10544093
    Abstract: The present invention relates to a compound of formula (I), or a tautomer and/or a pharmaceutically acceptable salt thereof Formula (I), and its uses to treat a disorder associated with protein misfolding stress and in particular with an accumulation of misfolded proteins.
    Type: Grant
    Filed: July 2, 2015
    Date of Patent: January 28, 2020
    Assignee: InFlectis BioScience
    Inventor: Philippe Guedat
  • Patent number: 10526297
    Abstract: The present invention relates to a compound of formula (I), or a tautomer and/or a pharmaceutically acceptable salt thereof, wherein R1 is alkyl, Cl, F or Br, R2 is H or F; R3 is selected from H and alkyl; R4 is selected from H and C(O)R6; R5 is H or R4 and R5 are linked to form a heterocyclic group which is optionally substituted with one or more R10 groups R6 is selected from R7, OR7 and NR8R6; R7R8 and R9 are each independently selected from alkyl, cycloalkyl, aralkyl, cycloalkenyl, heterocycyl and aryl, each of which is optionally substituted with one or more R10 groups; each R10 is independently selected from halogen, OH, CN NO1, COO-alkyl, aralkyl, SO2-alkyl, SO2-aryl, COOH, CO-alkyl, CO-aryl, NH2, NH-alkyl, N(alkyl)2, CF3, alkyl and alkoxy, X and Z are each independently CR11 and Y is selected from CR11 and N and R11 is H or F; for use in treating a disorder associated with protein misfolding stress and in particular associated with accumulation of misfolded proteins.
    Type: Grant
    Filed: August 31, 2018
    Date of Patent: January 7, 2020
    Assignees: InFlectis BioScience, United Kingdom Research and Innovation
    Inventors: Philippe Guedat, Anne Bertolotti
  • Publication number: 20180354914
    Abstract: The present invention relates to a compound of formula (I), or a tautomer and/or a pharmaceutically acceptable salt thereof, wherein R1 is alkyl, Cl, F or Br, R2 is H or F; R3 is selected from H and alkyl; R4 is selected from H and C(O)R6; R5 is H or R4 and R5 are linked to form a heterocyclic group which is optionally substituted with one or more R10 groups R6 is selected from R7, OR7 and NR8R6; R7R8 and R9 are each independently selected from alkyl, cycloalkyl, aralkyl, cycloalkenyl, heterocycyl and aryl, each of which is optionally substituted with one or more R10 groups; each R10 is independently selected from halogen. OH, CN NO2, COO-alkyl, aralkyl, SO2-alkyl, SO2-aryl, COOH, CO-alkyl, CO-aryl, NH2, NH-alkyl, N(alkyl)2, CF3, alkyl and alkoxy, X and Z are each independently CR11 and Y is selected from CR11 and N and R11 is H or F; for use in treating a disorder associated with protein misfolding stress and in particular associated with accumulation of misfolded proteins.
    Type: Application
    Filed: August 31, 2018
    Publication date: December 13, 2018
    Inventors: Philippe Guedat, Anne Bertolotti
  • Patent number: 10100020
    Abstract: The present invention relates to a compound of formula (I), or a tautomer and/or a pharmaceutically acceptable salt thereof, wherein: R1 is alkyl, Cl, F or Br; R2 is H or F; R3 is selected from H and alkyl; R4 is selected from H and C(O)R6; R5 is H; or R4 and R5 are linked to form a heterocyclic group which is optionally substituted with one or more R10 groups; R6 is selected from R7, OR7 and NR8R9; R7, R8 and R9 are each independently selected from alkyl, cycloalkyl, aralkyl, cycloalkenyl, heterocyclyl and aryl, each of which is optionally substituted with one or more R10 groups; each R10 is independently selected from halogen, OH, CN, NO2, COO-alkyl, aralkyl, SO2-alkyl, SO2-aryl, COOH, CO-alkyl, CO-aryl, NH2, NH-alkyl, N(alkyl)2, CF3, alkyl and alkoxy; X and Z are each independently CR11, and Y is selected from CR11 and N; and R11 is H or F; for use in treating a disorder associated with protein misfolding stress and in particular associated with accumulation of misfolded proteins.
    Type: Grant
    Filed: March 23, 2017
    Date of Patent: October 16, 2018
    Assignees: United Kingdom Research and Innovation, InFlectis BioScience
    Inventors: Philippe Guedat, Anne Bertolotti
  • Publication number: 20180221310
    Abstract: The present invention relates to a composition for use in treating a glioma or ameliorating the effects of a glioma, particularly glioblastoma, wherein said composition comprises a first active agent selected from the group consisting of a compound of formula (I), or a pharmaceutically acceptable salt thereof, (I) and a second active agent, which is temozolomide, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: July 26, 2016
    Publication date: August 9, 2018
    Inventors: Philippe GUEDAT, Pierre MINIOU
  • Publication number: 20170247344
    Abstract: The present invention relates to a compound of formula (I), or a tautomer and/or a pharmaceutically acceptable salt thereof, wherein: R1 is alkyl, Cl, F or Br; R2 is H or F; R3 is selected from H and alkyl; R4 is selected from H and C(O)R6; R5 is H; or R4 and R5 are linked to form a heterocyclic group which is optionally substituted with one or more R10 groups; R6 is selected from R7, OR7 and NR8R9; R7, R8 and R9 are each independently selected from alkyl, cycloalkyl, aralkyl, cycloalkenyl, heterocyclyl and aryl, each of which is optionally substituted with one or more R10 groups; each R10 is independently selected from halogen, OH, CN, NO2, COO-alkyl, aralkyl, SO2-alkyl, SO2-aryl, COOH, CO-alkyl, CO-aryl, NH2, NH-alkyl, N(alkyl)2, CF3, alkyl and alkoxy; X and Z are each independently CR11, and Y is selected from CR11 and N; and R11 is H or F; for use in treating a disorder associated with protein misfolding stress and in particular associated with accumulation of misfolded proteins.
    Type: Application
    Filed: March 23, 2017
    Publication date: August 31, 2017
    Inventors: Philippe Guedat, Anne Bertolotti
  • Patent number: 9682943
    Abstract: The present invention relates to a compound of formula (I), or a tautomer and/or a pharmaceutically acceptable salt thereof, wherein: R1 is alkyl, Cl, F or Br; R2 is H or F; R3 is selected from H and alkyl; R4 is selected from H and C(O)R6; R5 is H; or R4 and R5 are linked to form a heterocyclic group which is optionally substituted with one or more R10 groups; R6 is selected from R7, OR7 and NR8R9; R7, R8 and R9 are each independently selected from alkyl, cycloalkyl, aralkyl, cycloalkenyl, heterocyclyl and aryl, each of which is optionally substituted with one or more R10 groups; each R10 is independently selected from halogen, OH, CN, NO2, COO-alkyl, aralkyl, SO2-alkyl, SO2-aryl, COOH, CO-alkyl, CO-aryl, NH2, NH-alkyl, N(alkyl)2, CF3, alkyl and alkoxy; X and Z are each independently CR11, and Y is selected from CR11 and N; and R11 is H or F; for use in treating a disorder associated with protein misfolding stress and in particular associated with accumulation of misfolded proteins.
    Type: Grant
    Filed: January 10, 2014
    Date of Patent: June 20, 2017
    Assignees: MEDICAL RESEARCH COUNCIL, INFLECTIS BIOSCIENCE
    Inventors: Philippe Guedat, Anne Bertolotti
  • Publication number: 20170151196
    Abstract: The present invention relates to novel uses of a compound of formula (I), or a tautomer and/or a pharmaceutically acceptable salt thereof, in treating a disorder associated with the PPP1R15A pathway and associated with protein misfolding stress and in particular with accumulation of misfolded proteins selected in the group of tauopathies, synucleinopathies, polyglutamine and polyalanine diseases, leukodystrophies, cystic fibrosis, multiple sclerosis, lysosomal storage disorders, amyloidosis diseases, inflammation, metabolic disorders, cardio-vascular disorders, osteoporosis, nervous system trauma, ischemia.
    Type: Application
    Filed: July 2, 2015
    Publication date: June 1, 2017
    Inventor: Philippe GUEDAT
  • Publication number: 20170152220
    Abstract: The present invention relates to a compound of formula (I), or a tautomer and/or a pharmaceutically acceptable salt thereof Formula (I), and its uses to treat a disorder associated with protein misfolding stress and in particular with an accumulation of misfolded proteins.
    Type: Application
    Filed: July 2, 2015
    Publication date: June 1, 2017
    Inventor: Philippe GUEDAT
  • Publication number: 20160046589
    Abstract: The present invention relates to a compound of formula (I), or a tautomer and/or a pharmaceutically acceptable salt thereof, wherein: R1 is alkyl, Cl, F or Br; R2 is H or F; R3 is selected from H and alkyl; R4 is selected from H and C(O)R6; R5 is H; or R4 and R5 are linked to form a heterocyclic group which is optionally substituted with one or more R10 groups; R6 is selected from R7, OR7 and NR8R9; R7, R8 and R9 are each independently selected from alkyl, cycloalkyl, aralkyl, cycloalkenyl, heterocyclyl and aryl, each of which is optionally substituted with one or more R10 groups; each R10 is independently selected from halogen, OH, CN, NO2, COO-alkyl, aralkyl, SO2-alkyl, SO2-aryl, COOH, CO-alkyl, CO-aryl, NH2, NH-alkyl, N(alkyl)2, CF3, alkyl and alkoxy; X and Z are each independently CR11, and Y is selected from CR11 and N; and R11 is H or F; for use in treating a disorder associated with protein misfolding stress and in particular associated with accumulation of misfolded proteins.
    Type: Application
    Filed: January 10, 2014
    Publication date: February 18, 2016
    Inventors: Philippe Guedat, Anne Bertolotti
  • Patent number: 8648076
    Abstract: The present invention concerns new compounds of formula (I), their process of preparation and their therapeutic use.
    Type: Grant
    Filed: July 26, 2006
    Date of Patent: February 11, 2014
    Assignee: Hybrigenics SA
    Inventors: Philippe Guedat, Guillaume Boissy, Catherine Borg-Capra, Frédéric Colland, Laurent Daviet, Etienne Formstecher, Xavier Jacq, Jean-Christophe Rain, Rémi Delansorne, Stefania Vallese, Matteo Colombo
  • Publication number: 20120189579
    Abstract: The present invention concerns a substituted pyrrolidinone of the following formula I or a salt, solvate, tautomer, isotope, enantiomer, diastereoisomer or racemic mixture thereof: (I), for the treatment of hepatitis C.
    Type: Application
    Filed: July 9, 2010
    Publication date: July 26, 2012
    Applicant: VIVALIS
    Inventors: Amaya Berecibar, Philippe Guedat, Isabelle Valarche, Céline Mohamed-Arab, Christophe Matt
  • Publication number: 20120128630
    Abstract: The present invention concerns a 1-(6 members azo-heterocyclic)-pyrrolin-2-one compound of the following formula I or a salt, solvate, tautomer, isotope, enantiomer, diastereoisomer or racemic mixture thereof: the pharmaceutical composition thereof and their therapeutic use as inhibitors of Hepatitis C NS5B polymerase.
    Type: Application
    Filed: July 9, 2010
    Publication date: May 24, 2012
    Applicant: VIVALIS
    Inventors: Amaya Berecibar, Philippe Guedat, Céline Mohamed-Arab